• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改善糖尿病性黄斑水肿的临床管理:来自全球患者、医疗服务提供者和诊所工作人员调查的见解

Improving Clinical Management of Diabetic Macular Edema: Insights from a Global Survey of Patients, Healthcare Providers, and Clinic Staff.

作者信息

Ziemssen Focke, Sylvanowicz Michelle, Amoaku Winfried M, Aslam Tariq, Eldem Bora, Finger Robert P, Gale Richard P, Kodjikian Laurent, Korobelnik Jean-François, Lin Xiaofeng, Loewenstein Anat, Mitchell Paul, Murphy Moira, Owens David R, Parker Nick, Pearce Ian, Rodríguez Francisco J, Stern Jude, Talks S James, Wong David T, Wong Tien Yin, Barratt Jane

机构信息

University Eye Clinic, Department of Ophthalmology, University Hospital Leipzig, University of Leipzig, Leipzig, Germany.

Centre for Ophthalmology, Eberhard Karl University of Tübingen, Tübingen, Germany.

出版信息

Ophthalmol Ther. 2025 Jan;14(1):229-246. doi: 10.1007/s40123-024-01060-4. Epub 2024 Dec 14.

DOI:10.1007/s40123-024-01060-4
PMID:39673039
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11724817/
Abstract

INTRODUCTION

In contrast with patients receiving therapy for retinal disease during clinical trials, those treated in routine clinical practice experience various challenges (including administrative, clinic, social, and patient-related factors) that can often result in high patient and clinic burden, and contribute to suboptimal visual outcomes. The objective of this study was to understand the challenges associated with clinical management of diabetic macular edema from the perspectives of patients, healthcare providers, and clinic staff, and identify opportunities to improve eye care for people with diabetes.

METHODS

We conducted a survey of patients with diabetic macular edema, providers, and clinic staff in 78 clinics across 24 countries on six continents, representing a diverse range of individuals, healthcare systems, settings, and reimbursement models. Surveys comprised a series of single- and multiple-response questions completed anonymously. Data gathered included patient personal characteristics, challenges with appointment attendance, treatment experiences, and opportunities to improve support. Provider and clinic staff surveys asked similar questions about their perspectives; and clinic characteristics were also captured.

RESULTS

Overall, 5681 surveys were gathered: 3752 from patients with diabetic macular edema, 680 from providers, and 1249 from clinic staff. Too many appointments, too short treatment intervals, difficulties in traveling to the clinic or arranging adequate support to travel, out-of-pocket costs, office/parking fees, and long waiting times were noted by all as contributing to increase the burden on the patient and caregiver. Patients generally desired more in-depth discussions with their provider, which would help with information exchange and better expectation-setting.

CONCLUSIONS

The wealth of systematic data generated by this global survey highlights the breadth and scale of challenges associated with the clinical management of patients with diabetic macular edema. Addressing the opportunities for improvement raised by patients, providers, and clinic staff could increase patient adherence to treatment, reduce appointment burden, and improve clinic capacity.

摘要

引言

与在临床试验中接受视网膜疾病治疗的患者不同,在常规临床实践中接受治疗的患者会面临各种挑战(包括管理、诊所、社会和患者相关因素),这些挑战通常会导致患者和诊所负担加重,并导致视觉效果欠佳。本研究的目的是从患者、医疗服务提供者和诊所工作人员的角度了解与糖尿病性黄斑水肿临床管理相关的挑战,并确定改善糖尿病患者眼部护理的机会。

方法

我们对来自六大洲24个国家的78家诊所的糖尿病性黄斑水肿患者、医疗服务提供者和诊所工作人员进行了调查,这些诊所代表了不同类型的个人、医疗系统、环境和报销模式。调查包括一系列匿名完成的单项和多项选择题。收集的数据包括患者个人特征、预约就诊的挑战、治疗经历以及改善支持的机会。医疗服务提供者和诊所工作人员的调查问卷询问了他们对类似问题的看法;同时还收集了诊所的特征信息。

结果

总体而言,共收集到5681份调查问卷:3752份来自糖尿病性黄斑水肿患者,680份来自医疗服务提供者,1249份来自诊所工作人员。所有人都指出,预约过多、治疗间隔过短、前往诊所就诊困难或难以安排足够的出行支持、自付费用、办公/停车费用以及长时间等待等因素导致患者和护理人员负担加重。患者普遍希望与医疗服务提供者进行更深入的讨论,这将有助于信息交流并更好地设定预期。

结论

这项全球调查产生的大量系统数据凸显了与糖尿病性黄斑水肿患者临床管理相关挑战的广度和规模。解决患者、医疗服务提供者和诊所工作人员提出的改进机会可以提高患者对治疗的依从性,减轻预约负担,并提高诊所的服务能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/11724817/e05218bf966e/40123_2024_1060_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/11724817/6e50bd7e67d9/40123_2024_1060_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/11724817/e05218bf966e/40123_2024_1060_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/11724817/6e50bd7e67d9/40123_2024_1060_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/11724817/e05218bf966e/40123_2024_1060_Fig2_HTML.jpg

相似文献

1
Improving Clinical Management of Diabetic Macular Edema: Insights from a Global Survey of Patients, Healthcare Providers, and Clinic Staff.改善糖尿病性黄斑水肿的临床管理:来自全球患者、医疗服务提供者和诊所工作人员调查的见解
Ophthalmol Ther. 2025 Jan;14(1):229-246. doi: 10.1007/s40123-024-01060-4. Epub 2024 Dec 14.
2
Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration.患者、医护人员及工作人员对新生血管性年龄相关性黄斑变性管理挑战与解决方案的全球见解
Ophthalmol Ther. 2025 Jan;14(1):211-228. doi: 10.1007/s40123-024-01061-3. Epub 2024 Dec 14.
3
Mobile technologies to support healthcare provider to healthcare provider communication and management of care.支持医疗服务提供者之间沟通及护理管理的移动技术。
Cochrane Database Syst Rev. 2020 Aug 18;8(8):CD012927. doi: 10.1002/14651858.CD012927.pub2.
4
Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.抗血管内皮生长因子治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿的患者体验调查。
Ophthalmic Res. 2024;67(1):311-321. doi: 10.1159/000538975. Epub 2024 Apr 29.
5
Caregiver Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration.抗血管内皮生长因子治疗糖尿病性黄斑水肿和新生血管性年龄相关性黄斑变性的护理人员体验调查。
Ophthalmic Res. 2024;67(1):516-527. doi: 10.1159/000540390. Epub 2024 Aug 29.
6
Health Care Needs, Experiences, and Perspectives of Autistic Adults.成年自闭症患者的医疗保健需求、经历及观点
Autism Adulthood. 2023 Mar 1;5(1):51-62. doi: 10.1089/aut.2021.0069. Epub 2023 Mar 13.
7
Associations Between Primary Care Providers and Staff-Reported Access Management Challenges and Patient Perceptions of Access.初级保健提供者与员工报告的获取管理挑战之间的关联,以及患者对获取的看法。
J Gen Intern Med. 2023 Oct;38(13):2870-2878. doi: 10.1007/s11606-023-08172-w. Epub 2023 Aug 2.
8
Improving Sexual and Gender Minority Cancer Care: Patient and Caregiver Perspectives From a Multi-Methods Pilot Study.改善性少数群体和性别少数群体的癌症护理:一项多方法试点研究中患者和护理人员的观点
Front Oncol. 2022 May 6;12:833195. doi: 10.3389/fonc.2022.833195. eCollection 2022.
9
Patient-Centered Economic Burden of Diabetic Macular Edema: Retrospective Cohort Study.患者为中心的糖尿病性黄斑水肿的经济负担:回顾性队列研究。
JMIR Public Health Surveill. 2024 Oct 8;10:e56741. doi: 10.2196/56741.
10
Developing an efficient scheduling template of a chemotherapy treatment unit: A case study.制定化疗治疗单元的高效排班模板:一项案例研究。
Australas Med J. 2011;4(10):575-88. doi: 10.4066/AMJ.2011.837. Epub 2011 Oct 31.

引用本文的文献

1
Challenges and Opportunities for Improving Management of Patients with nAMD and DME in China: Insights from a Global Survey on Anti-VEGF Therapy.中国改善湿性年龄相关性黄斑变性和糖尿病性黄斑水肿患者管理的挑战与机遇:抗VEGF治疗全球调查的见解
Adv Ther. 2025 Jun 27. doi: 10.1007/s12325-025-03280-x.
2
Planned vs. Performed Treatment Regimens in Diabetic Macular Edema: Real-World Evidence from the PACIFIC Study.糖尿病性黄斑水肿的计划治疗方案与实际执行治疗方案:来自太平洋研究的真实世界证据
J Clin Med. 2025 Apr 30;14(9):3120. doi: 10.3390/jcm14093120.

本文引用的文献

1
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.玻璃体内注射阿柏西普 8mg 治疗糖尿病黄斑水肿(PHOTON):一项随机、双盲、非劣效、2/3 期临床试验的 48 周结果。
Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7.
2
Real-World Persistence and Treatment Interval in Patients with Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factors in the USA.美国抗血管内皮生长因子治疗糖尿病性黄斑水肿患者的真实世界持续治疗情况及治疗间隔
Ophthalmol Ther. 2023 Oct;12(5):2465-2477. doi: 10.1007/s40123-023-00750-9. Epub 2023 Jun 22.
3
Intravitreal aflibercept for the treatment of patients with diabetic macular edema in routine clinical practice in Latin America: the AQUILA study.
阿柏西普玻璃体内注射用于拉丁美洲常规临床实践中糖尿病性黄斑水肿患者的治疗:AQUILA研究
Int J Retina Vitreous. 2022 Aug 2;8(1):52. doi: 10.1186/s40942-022-00396-y.
4
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.在糖尿病性黄斑水肿(YOSEMITE 和 RHINE)患者中,每 16 周进行一次玻璃体腔内 faricimab 延长给药的疗效、持久性和安全性:两项随机、双盲、3 期试验。
Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24.
5
Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration.定义新生血管性年龄相关性黄斑变性抗血管内皮生长因子治疗的不依从和不持续。
JAMA Ophthalmol. 2021 Jul 1;139(7):769-776. doi: 10.1001/jamaophthalmol.2021.1660.
6
Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study).雷珠单抗长期治疗糖尿病性黄斑水肿患者的真实世界转归(VISION研究)
Clin Ophthalmol. 2020 Dec 2;14:4173-4185. doi: 10.2147/OPTH.S281501. eCollection 2020.
7
Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study.2020 年失明和视力障碍的原因及 30 多年来的趋势,以及与 VISION 2020:看见的权利相关的可避免盲的患病率:全球疾病负担研究的分析。
Lancet Glob Health. 2021 Feb;9(2):e144-e160. doi: 10.1016/S2214-109X(20)30489-7. Epub 2020 Dec 1.
8
Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed-Methods Systematic Review.抗 VEGF 药物治疗新生血管性年龄相关性黄斑变性的不依从或不持续治疗:一项混合方法系统评价。
Ophthalmology. 2021 Feb;128(2):234-247. doi: 10.1016/j.ophtha.2020.07.060. Epub 2020 Aug 5.
9
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.玻璃体内注射阿柏西普按需治疗方案治疗渗出性年龄相关性黄斑变性的疗效和安全性:ALTAIR 随机对照研究的 52 周和 96 周结果。
Adv Ther. 2020 Mar;37(3):1173-1187. doi: 10.1007/s12325-020-01236-x. Epub 2020 Feb 3.
10
Predictors of Patient Satisfaction and the Perceived Quality of Healthcare in an Emergency Department in Portugal.预测葡萄牙急诊科患者满意度和医疗服务质量感知的因素。
West J Emerg Med. 2020 Jan 27;21(2):391-403. doi: 10.5811/westjem.2019.9.44667.